Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa)

Inclusion Criteria: * Age ≥ 20 years. Patients with locally advanced or metastatic solid tumors harboring deficiency or alteration of anaplastic lymphoma kinase (ALK) tyrosine kinase. Disease progression during or within 6 months after completion of standard therapy, or no appropriate standard treatment available. At least one measurable lesion according to applicable response evaluation criteria. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Estimated life expectancy of at least 8 weeks. Exclusion Criteria: * Known hypersensitivity to crizotinib or alectinib. Current or prior use of ALK inhibitors. Current use of tyrosine kinase inhibitors. Receipt of radiotherapy within 2 weeks prior to study entry. Palliative radiotherapy to non-target lesions is permitted. History of other malignancies, except for osteosarcoma or chondrosarcoma, unless the patient has been disease-free for at least 2 years. Exceptions include adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. Liver cirrhosis with a Child-Pugh score ≥ 8. Uncorrectable electrolyte abnormalities. Presence of brain metastases. Active acute infection. Significant unresolved toxicity from prior therapy. Comorbid conditions that may interfere with study participation, including but not limited to uncontrolled diabetes mellitus, autoimmune diseases, or any condition that, in the investigator's judgment, renders the patient unsuitable for…